Article
Bispecific antibodies targeting mutant RAS neoantigens.
Science immunology - 1 Mar 2021
Douglass Jacqueline, Hsiue Emily Han-Chung, Mog Brian J, Hwang Michael S, DiNapoli Sarah R, Pearlman Alexander H, Miller Michelle S, Wright Katharine M, Azurmendi P Aitana, Wang Qing, Paul Suman, Schaefer Annika, Skora Andrew D, Molin Marco Dal, Konig Maximilian F, Liu Qiang, Watson Evangeline, Li Yana, Murphy Michael B, Pardoll Drew M, Bettegowda Chetan, Papadopoulos Nickolas, Gabelli Sandra B, Kinzler Kenneth W, Vogelstein Bert, Zhou Shibin
Abstract excerpt
Mutations in the RAS oncogenes occur in multiple cancers, and ways to target these mutations has been the subject of intense research for decades. Most of these efforts are focused on conventional small-molecule drugs rather than antibody-based therapies because the RAS proteins are intracellular. Peptides derived from recurrent RAS mutations, G12V and Q61H/L/R, are presented on cancer cells in the context of two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.